Asymptomatic: to have no symptoms of disease; evidence of disease
is not noticeable by the patient
Aqueous humor: the clear fluid that
flows through and fills the space in front of the lens of the eye. It nourishes
the lens and cornea and helps maintain pressure within the eye. Increased intraocular
pressure and glaucoma can result when the aqueous humor cannot drain normally.
Chronic: a disease having a long duration, typically a lifelong
condition that can be treated but not cured
Cornea: the transparent, bowl-shaped structure at the front of
the eye covering the iris and the pupil
Cupping: the indentation in the optic disc; cupping can increase
(deepen) over time as a result of progression of glaucoma disease
Diminishes: reduces; lessens
Disease progression: the worsening of a disease characterized by
increased tissue or organ damage and/or worsening of symptoms (eg, deterioration
of vision)
Elevated IOP: raised or increased intraocular
pressure; high eye pressure
Glaucoma: a group of eye diseases (many different types) resulting
in damage to the optic nerve; commonly characterized by elevated IOP; can lead to
blindness if left untreated
Glaucomatous: related to or affected by glaucoma
Gradual: changing little by little over time
Hyperemia: conjunctival hyperemia is the medical term for increased
eye redness
IOP: intraocular pressure; the pressure within
the eyes
Irreversible: not able to be corrected; permanent
LUMIGAN®: An eyedrop medication used to lower elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
mm Hg: millimeters of mercury; how IOP is measured
Normal-pressure glaucoma: a type of open-angle glaucoma in which
IOP is within normal range, yet the optic nerve is still damaged and there is a
visual field defect; also called low-tension or normal-tension glaucoma
Ocular hypertension: consistent
elevated eye pressure (IOP); high IOP but without any detectable visual field defect
or optic nerve damage
Open-angle glaucoma: the most common
form of glaucoma; typically characterized by chronic elevated IOP, optic nerve damage,
and visual field loss
Ophthalmoscope: a medical device used to view the interior of the
eye (including the optic nerve head)
Optic disc: area in the back of the eye where the optic nerve leaves
the eye
Optic nerve: the nerve that carries visual
images from the eye, specifically the retina, to the brain
Perimetry test: a test that measures an individual’s visual field
(range of vision); also called visual field test
Peripheral vision: area of view
that is not the center focus; eg, side vision or what you may see “out of the corner
of your eye”
Primary: the first or of the highest rank of importance
Retina: the innermost layer of the eye; sends visual images as
electrical messages through the optic nerve to the brain
RGCs: retinal ganglion cells; found in the retina, convert images
received into electrical messages, and then send those messages to the optic nerve
Risk factor: a medical, hereditary, or behavioral characteristic
associated with increased likelihood of developing a disease
Tonometry: a type of test used to measure IOP (eye pressure)
Visual field: the entire field of vision, central and peripheral;
measured by a perimetry test
Visual field defect: a missing area or spot in the visual field;
in patients with glaucoma, the first sign of visual field defect typically occurs
in the peripheral or side vision
Visual field loss: in patients with
glaucoma, it is the deterioration of vision over time; typically, the side or peripheral
vision is lost first, characterized by a narrowing of what is seen outside of center
focus
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) is used
for the treatment of high eye pressure, also called intraocular pressure (IOP),
in people with open-angle glaucoma or ocular hypertension.
Important Safety Information
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) has been
reported to cause darkening (pigmentation) of eye color, eyelid skin, and eyelashes
as well as increased growth of eyelashes. Pigmentation changes can increase as long
as LUMIGAN® 0.01% and 0.03% is used. After stopping LUMIGAN®
0.01% and 0.03%, darkening of eye color is likely to be permanent, while darkening
of the eyelid skin and eyelash changes may be reversible. The effects of increased
darkening beyond 5 years are not known.
When only one eye is treated, there is a possibility of eyelash changes in the eye
treated with LUMIGAN® 0.01% and 0.03%. These changes may result in
differences between the eyes in eyelash length, thickness, darkness, number of eyelashes,
and/or direction of eyelash growth. These changes are usually reversible upon stopping
LUMIGAN® 0.01% and 0.03% therapy.
Avoid allowing the tip of the dispensing bottle to touch the eye, anything around
the eye, fingers, or any other surface in order to avoid contamination by common
bacteria known to cause eye infections. Serious damage to the eye and loss of vision
may result from using contaminated solutions.
If you have eye surgery or develop any eye reactions (such as trauma or infection),
immediately consult with your physician about continuing the use of LUMIGAN®
0.01% and 0.03%.
If you wear contact lenses, remove them before using LUMIGAN® 0.01%
and 0.03%. Then wait 15 minutes after using LUMIGAN® 0.01% and 0.03%
before you put your contacts back into your eyes.
The most common side effects are eye redness, growth of eyelashes, and itchy eyes.
Click here
for full prescribing information.